关注
Zalmai Hakimi
Zalmai Hakimi
Sobi
在 sobi.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison
K Maman, S Aballea, J Nazir, K Desroziers, ME Neine, E Siddiqui, ...
European urology 65 (4), 755-765, 2014
3242014
Rate, degree, and predictors of recovery from disability following ischemic stroke
GJ Hankey, J Spiesser, Z Hakimi, G Bego, P Carita, S Gabriel
Neurology 68 (19), 1583-1587, 2007
2662007
Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis
C Kelleher, Z Hakimi, R Zur, E Siddiqui, K Maman, S Aballéa, J Nazir, ...
European urology 74 (3), 324-333, 2018
2202018
Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice
CR Chapple, J Nazir, Z Hakimi, S Bowditch, F Fatoye, F Guelfucci, ...
European urology 72 (3), 389-399, 2017
2182017
Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey
D Léger, CM Morin, M Uchiyama, Z Hakimi, S Cure, JK Walsh
Sleep medicine 13 (1), 43-51, 2012
1622012
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
G Yeowell, P Smith, J Nazir, Z Hakimi, E Siddiqui, F Fatoye
BMJ open 8 (11), e021889, 2018
1182018
Qualitative exploration of the patient experience of underactive bladder
AD Uren, N Cotterill, C Harding, C Hillary, C Chapple, M Klaver, ...
European urology 72 (3), 402-407, 2017
852017
Time frame and predictors of recovery from disability following recurrent ischemic stroke
GJ Hankey, J Spiesser, Z Hakimi, P Carita, S Gabriel
Neurology 68 (3), 202-205, 2007
722007
Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder
SM Notte, TS Marshall, M Lee, Z Hakimi, I Odeyemi, WH Chen, ...
BMC urology 12, 1-8, 2012
602012
Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy
S MacDiarmid, S Al-Shukri, J Barkin, A Fianu-Jonasson, P Grise, ...
The Journal of Urology 196 (3), 809-818, 2016
572016
Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting
Z Hakimi, S Aballéa, S Ferchichi, M Scharn, IA Odeyemi, M Toumi, ...
Transplant Infectious Disease 19 (5), e12732, 2017
492017
Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and …
D Robinson, C Kelleher, D Staskin, ER Mueller, C Falconer, J Wang, ...
Neurourology and Urodynamics 37 (1), 394-406, 2018
452018
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms
CR Chapple, MJ Drake, P Van Kerrebroeck, L Cardozo, T Drogendijk, ...
BJU international 113 (5), 696-703, 2014
452014
Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom
J Nazir, K Maman, ME Neine, B Briquet, IAO Odeyemi, Z Hakimi, ...
Value in Health 18 (6), 783-790, 2015
342015
Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom
S Aballéa, K Maman, K Thokagevistk, J Nazir, IAO Odeyemi, Z Hakimi, ...
Clinical Drug Investigation 35, 83-93, 2015
332015
Patient‐reported outcomes with the β3‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
V Khullar, G Amarenco, JC Angulo, MB Blauwet, J Nazir, IA Odeyemi, ...
Neurourology and Urodynamics 35 (8), 987-994, 2016
312016
Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
K Desroziers, S Aballéa, K Maman, J Nazir, I Odeyemi, Z Hakimi
Health and Quality of Life Outcomes 11, 1-9, 2013
282013
Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a …
Z Hakimi, M Johnson, J Nazir, B Blak, IAO Odeyemi
Current medical research and opinion 31 (1), 43-50, 2015
272015
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from …
D Castro-Diaz, CR Chapple, Z Hakimi, MB Blauwet, L Delgado-Herrera, ...
Quality of Life Research 24, 1719-1727, 2015
262015
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta …
J Nazir, C Kelleher, S Aballea, K Maman, Z Hakimi, C Mankowski, ...
Neurourology and Urodynamics 37 (3), 986-996, 2018
242018
系统目前无法执行此操作,请稍后再试。
文章 1–20